CA3235602A1 - Compounds for the treatment of kinase-dependent disorders - Google Patents

Compounds for the treatment of kinase-dependent disorders Download PDF

Info

Publication number
CA3235602A1
CA3235602A1 CA3235602A CA3235602A CA3235602A1 CA 3235602 A1 CA3235602 A1 CA 3235602A1 CA 3235602 A CA3235602 A CA 3235602A CA 3235602 A CA3235602 A CA 3235602A CA 3235602 A1 CA3235602 A1 CA 3235602A1
Authority
CA
Canada
Prior art keywords
ppm
less
compound
degradants
contaminants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3235602A
Other languages
English (en)
French (fr)
Inventor
Khalid Shah
Frenel Demorin
Sagar Shakya
Yong Wang
Wei Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CA3235602A1 publication Critical patent/CA3235602A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3235602A 2021-11-03 2022-11-03 Compounds for the treatment of kinase-dependent disorders Pending CA3235602A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163275255P 2021-11-03 2021-11-03
US63/275,255 2021-11-03
PCT/US2022/048770 WO2023081253A1 (en) 2021-11-03 2022-11-03 Compounds for the treatment of kinase-dependent disorders

Publications (1)

Publication Number Publication Date
CA3235602A1 true CA3235602A1 (en) 2023-05-11

Family

ID=84462825

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3235602A Pending CA3235602A1 (en) 2021-11-03 2022-11-03 Compounds for the treatment of kinase-dependent disorders

Country Status (9)

Country Link
US (1) US20250051284A1 (https=)
EP (1) EP4426678A1 (https=)
JP (1) JP2024539721A (https=)
CN (1) CN118176182A (https=)
AR (1) AR127561A1 (https=)
AU (1) AU2022383160A1 (https=)
CA (1) CA3235602A1 (https=)
TW (1) TW202334090A (https=)
WO (1) WO2023081253A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117402114A (zh) * 2018-01-26 2024-01-16 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117402114A (zh) * 2018-01-26 2024-01-16 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
KR102828472B1 (ko) * 2018-12-13 2025-07-03 엑셀리시스, 인코포레이티드 키나아제 억제제의 결정질 형태 및 염 형태
MX2021014773A (es) * 2019-06-03 2022-01-18 Exelixis Inc Formas de sales cristalinas de un inhibidor de cinasas.
CN115461328B (zh) * 2020-04-30 2025-11-07 埃克塞里艾克西斯公司 用于制备激酶抑制剂的方法
JP2023548855A (ja) * 2020-11-05 2023-11-21 エグゼリクシス， インコーポレイテッド キナーゼ阻害剤の医薬組成物

Also Published As

Publication number Publication date
CN118176182A (zh) 2024-06-11
AR127561A1 (es) 2024-02-07
WO2023081253A1 (en) 2023-05-11
US20250051284A1 (en) 2025-02-13
AU2022383160A1 (en) 2024-05-02
JP2024539721A (ja) 2024-10-29
EP4426678A1 (en) 2024-09-11
TW202334090A (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
AU2018220045B2 (en) C-met modulator pharmaceutical compositions
CA2728541C (en) Crystalline forms of thiazolidinedione compound and its manufacturing method
CN106008462A (zh) 一种alk抑制剂的结晶形式
US11820772B2 (en) Polymorphs of the hydrochloride salt of linaprazan glurate
CN102002035A (zh) 甲磺酸伊马替尼的δ和ε晶形
JP2008539278A (ja) 結晶性ロスバスタチンカルシウム
CA3235602A1 (en) Compounds for the treatment of kinase-dependent disorders
JP2019055960A (ja) 薬学的に活性な化合物の固体形態
WO2024095127A1 (en) Solid state forms of tivozanib and process for preparation thereof
WO2022086899A1 (en) Solid state forms of pralsetinib and process for preparation thereof
EP4349835A1 (en) Hydrate crystal form of lazertinib methanesulfonate, preparation method therefor and use thereof

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241030

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241030

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241030

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251022

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251022